1. Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries.
- Author
-
Moots RJ, Ostor AJ, Loft AG, Järvinen P, Larsson P, Ekelund M, Reynolds A, Kielar D, Lindkvist RM, and Qvitzau S
- Subjects
- Adult, Aged, Antirheumatic Agents adverse effects, Antirheumatic Agents economics, Efficiency, Employment, Etanercept, Female, Humans, Immunoglobulin G adverse effects, Immunoglobulin G economics, Male, Middle Aged, Sick Leave statistics & numerical data, Spondylitis, Ankylosing economics, Treatment Outcome, Young Adult, Antirheumatic Agents administration & dosage, Health Care Costs, Immunoglobulin G administration & dosage, Quality of Life, Receptors, Tumor Necrosis Factor administration & dosage, Spondylitis, Ankylosing drug therapy
- Abstract
Objective: To characterize the impact of etanercept (ETN) in AS on cost, work productivity and quality of life (QoL)., Methods: A Phase 4, open-label, multi-centre (UK, Scandinavia) extension study in AS. Eligible subjects (n = 84) were treated for 36-52 weeks with ETN 50 mg s.c. once weekly. Analysis included direct costs (transformed out-patient and in-patient care elements), indirect costs (sick leave and lost working days), efficacy and QoL., Results: Annualized direct and indirect costs decreased (55.5%, P ≤ 0.008) during ETN treatment, as did out-patient and in-patient episodes (physiotherapist/physician visits, P = 0.012). Work productivity and QoL increased., Conclusion: ETN therapy significantly reduces direct and indirect health-care costs and increases work ability and QoL in AS. Trial Registration. EUDRACT, https://eudract.ema.europa.eu/, 2006-001061-42.
- Published
- 2012
- Full Text
- View/download PDF